Virtual Library

 x 
My Library Virtual Library FAQ

Start Your Search

X. Le



Author of

  • +

    P2.02 - Biology/Pathology (ID 616)

    • Event: WCLC 2017
    • Type: Poster Session with Presenters Present
    • Track: Biology/Pathology
    • Presentations: 1
    • +

      P2.02-003 - A Practical Prognostic lncRNA Signature for Lung Squamous Cell Carcinoma (ID 7979)

      09:30 - 09:30  |  Author(s): X. Le

      • Abstract
      • Slides

      Background:
      This study aimed to develop and assess a practical prognostic lncRNA signature for squamous cell carcinoma of the lung (LUSC).

      Method:
      RNA expression profile and clinical data from 388 LUSC patients were accessed and download from the Cancer Genome Atlas (TCGA) database. Differential lncRNA expression was compared and analyzed between normal tissue and tumor samples. By univariate and multivariate Cox regression analyses, a seven-lncRNA signature was developed and used for the purpose of survival prediction in LUSC patients. We applied receiver operating characteristic analysis to assess the performance of our model.

      Result:
      Sixteen out of 1414 differentially expressed lncRNAs in the TCGA dataset were associated with the overall survival of LUSC patients. Risk score analysis was used to select 7 lncRNAs to be included in our model development and validation. The ROC analysis indicated that the specificity and sensitivity of this profile are high. Figure 1 Figure 1. Kaplan-Meier and ROC curves for the 7-lncRNA signature in the validation set. (A) The differences between the high-risk (n=103) and low-risk (n=91) groups were determined by the log-rank test (p<0.0001). Five year overall survival was 36.8% (95% CI: 26.1%-51.8%) and 61.9% (95% CI: 51.4%-74.6%) for the high-risk and low-risk groups, respectively. (B) ROC curves indicated that the area under receiver operating characteristic of 7-lncRNA model was 0.685.



      Conclusion:
      The current study identified a seven-lncRNA signature that predicts the outcome of LUSC, offering potentially novel therapeutic targets for the treatment of squamous cell carcinoma of the lung.

      Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.